Synapse

← Otávio Berwanger

Papers by Otávio Berwanger

Page 1 · newest first

  1. Intensive Blood-Pressure Lowering in Patients with Type 2 DiabetesNew England Journal of Medicine · 2026
  2. Intensive Blood-Pressure Control in Patients with Previous Ischemic StrokeNew England Journal of Medicine · 2026
  3. Classifying lipid lowering intensity in the era of combination therapy: A proposal to define very high intensity regimensEuropean Journal of Preventive Cardiology · 2026
  4. Intensive blood-pressure control for the prevention of major cardiovascular events in patients with type 2 diabetes: Rationale, design and baseline characteristics of the OPTIMAL-DIABETES randomized trialAmerican Heart Journal · 2026
  5. Intensive blood-pressure control for the prevention of major cardiovascular events in stroke patients: rationale and design of the OPTIMAL-STROKE trialEuropean Stroke Journal · 2026
  6. Community health and well-being workers (CHWWs) for preventive healthcare services uptake in the UK: a cluster-randomised controlled trial protocolBMJ Open · 2026
  7. Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCIJournal of the American College of Cardiology · 2024
  8. Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMIJournal of the American College of Cardiology · 2025
  9. 2026 iCARDIO Alliance Global Implementation Guidelines on Ischemic Heart DiseaseGlobal Cardiology · 2026
  10. Cardiovascular Care in Brazil: Current Status, Challenges, and OpportunitiesCirculation · 2022
  11. Safety and outcomes of dapagliflozin initiation in critically ill patients with acute kidney injury: A post-hoc analysis of the defender trialJournal of Critical Care · 2026
  12. Digitally Enabled Quality Improvement Intervention and LDL-C Control in Atherosclerotic Cardiovascular DiseaseJAMA Cardiology · 2026
  13. Randomized Trial of Effect of Bariatric Surgery on Blood Pressure After 5 YearsJournal of the American College of Cardiology · 2024
  14. Adverse Effects and Treatment Discontinuation of Blood Pressure–Lowering Drugs and CombinationsJAMA · 2026
  15. Clinical Characterization of Patients With 5q Spinal Muscular Atrophy Types 2 and 3 in Brazil: A Cross‐Sectional Observational StudyClinical Genetics · 2026
  16. Abstract Number: Esoc2026lb174 Intensive Blood-Pressure Control for the Prevention of Major Cardiovascular Events in Stroke Patients: Rational, Design and Baseline Characteristics of the Optimal-Stroke TrialEuropean Stroke Journal · 2026
  17. Rationale and design of a pragmatic randomized clinical trial assessing a smartphone-based digital health intervention in hypertension: The ELFIE-HYPERTENSION trialAmerican Heart Journal · 2026
  18. Blood pressure control in patients using the elfie self-monitoring and gamified mobile health application: a real-world evidence study involving over 22,000 users from 3 middle-income countriesEuropean Heart Journal - Digital Health · 2026
  19. Prasugrel or ticagrelor monotherapy vs dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndromes: a landmark analysis from the NEO-MINDSET trialEuropean Heart Journal · 2025
  20. Abstract 4338221: EVOLocumab Very Early after Myocardial Infarction (EVOLVE-MI): A Pragmatic Randomized Multicenter International Trial - Design and Baseline CharacteristicsCirculation · 2025
  21. Innovative design and modelling to improve sex and gender analysis in clinical trialsBMJ · 2025
  22. Influenza Vaccination for Prevention of Death and Major Cardiovascular Events in Patients With a History of Stroke: A Subanalysis of the Vip-Acs Trial.2025
  23. Efficacy and Safety of a Novel Triple Single-Pill For Uncontrolled Hypertension: the OPTION TREAT TrialJACC Advances · 2025
  24. Polypill and RiskOMeter to Prevent StrOke and CogniTive ImpairmEnt in Primary Health Care (PROMOTE) Randomized Clinical Trial: Rationale and DesignNeuroepidemiology · 2025
  25. Early Withdrawal of Aspirin after PCI in Acute Coronary SyndromesNew England Journal of Medicine · 2025
  26. Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trialCardiovascular Diabetology · 2025
  27. Effects of dapagliflozin on urinary output, fluid balance, and biochemistry in critically ill patients: a post-hoc secondary analysis of the DEFENDER trialCritical Care · 2025
  28. Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trialsThe Lancet Respiratory Medicine · 2025
  29. Electrocardiographic Left Ventricular Mass Trajectories and the Effects of Treatment in Patients at Different Stages of HypertensionJournal of Clinical Medicine · 2025
  30. Rationale, design and prerandomization data for a cluster randomized trial to assess the effect of a digitally enabled quality improvement intervention on LDL-C control in established atherosclerotic cardiovascular disease patients: The SAPPHIRE-LDL trialAmerican Heart Journal · 2025
  31. Clinical Trials in Hypertension: A Mathematical Endorsement for Diagnosis and TreatmentHypertension · 2024
  32. Effect of Tele-ICU on Clinical Outcomes of Critically Ill PatientsJAMA · 2024
  33. Amiodarone or Implantable Cardioverter-Defibrillator in Chagas CardiomyopathyJAMA Cardiology · 2024
  34. Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trialsThe Lancet Diabetes & Endocrinology · 2024
  35. Advancing healthcare with artificial intelligence: diagnostic accuracy of machine learning algorithm in diagnosis of diabetic retinopathy in the Brazilian populationDiabetology & Metabolic Syndrome · 2024
  36. Dapagliflozin for Critically Ill Patients With Acute Organ DysfunctionJAMA · 2024
  37. The relative merits of using a high-sensitivity cardiac Troponin T assay compared to a nonhigh-sensitivity troponin T assay after noncardiac surgeryAmerican Heart Journal · 2024
  38. COVID-19 Vaccination and Cardiopulmonary Events After Acute Coronary SyndromesJAMA Network Open · 2024
  39. Mortality and major postoperative complications within one year after vascular surgery: a prospective cohort studyPolskie Archiwum Medycyny Wewnętrznej · 2024
  40. Longitudinal data collection in pediatric and adult patients with 5q spinal muscular atrophy in Latin America: LATAM RegistrAME study - a clinical registry study protocolEinstein (São Paulo) · 2024
  41. Mortality, hospitalizations, and persistence of symptoms in the outpatient setting of the first COVID-19 wave in Brazil: results of SARS-Brazil cohort studyEinstein (São Paulo) · 2024
  42. Myocardial Infarction with ST Elevation and Reperfusion Therapy in Brazil: Data from the ACCEPT RegistryArquivos Brasileiros de Cardiologia · 2024
  43. Association Between Body Mass Index, Obesity, and Clinical Outcomes Following Coronary Artery Bypass Grafting in Brazil: An Analysis of One Year of Follow-up of BYPASS Registry PatientsBrazilian Journal of Cardiovascular Surgery · 2024
  44. Impact of a quality programme on overindication of surgeries for endometriosis and cholecystectomiesBMJ Open Quality · 2023
  45. One-year Outcomes after Discharge from Noncardiac Surgery and Association between Predischarge Complications and Death after Discharge: Analysis of the VISION Prospective Cohort StudyAnesthesiology · 2023
  46. The effects of canagliflozin in type 2 diabetes in subgroups defined by population‐specific body mass index: Insights from the CANVAS Program and CREDENCE trialDiabetes Obesity and Metabolism · 2023
  47. P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET TrialEuroIntervention · 2023
  48. Assessing statins use in a real-world primary care digital strategy: a cross-sectional analysis of a population-wide digital health approachThe Lancet Regional Health - Americas · 2023
  49. Effect of P2Y12 Inhibitors on Organ Support–Free Survival in Critically Ill Patients Hospitalized for COVID-19JAMA Network Open · 2023
  50. Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE – COALITION VIII randomised clinical trialEClinicalMedicine · 2023